OCTOBER 29, 2021
CRN-I webinars to examine women’s nutritional needs for optimal health through lifecycle
Emphasizing a need for science-based policy-making, CRN-International has gathered international experts to share insights from recent research focusing on women’s health.
Kicking off next week, CRN-I will present a complementary webinar series designed for Codex delegates—and open to CRN members.
Why it matters: Established and emerging nutritional interventions can impact the trajectory of the healthspan in women.
-
From infancy and early childhood, to pregnancy and lactation, and beyond post-menopause, women’s life stages present opportunities to enhance wellbeing across populations in both developed and developing countries.
Save the dates and register to participate on:
-
Friday, Nov. 5, 6:30–8:00 am ET
-
Wednesday, Nov. 10, 10:00–11:30 am ET
-
Monday, Dec. 6, 3:30–5:00 pm ET
The first session will cover hidden hunger and consequences in German children along with challenges and opportunities looking at adolescent nutrition globally. Visit the CRN-I website for additional session details and registration.
Flashback Friday: DSHEA enacted 27 years ago—see what stakeholders are saying now
We couldn’t let October end without a nod to the Dietary Supplement Health and Education Act of 1994—DSHEA—that all-important law upon which this now $56 billion industry is built.
Signed into law on Oct. 25, 1994, DSHEA struck a balance between proof of safety and consumer access, as CRN’s Steve Mister explained in a NutraIngredients-USA article earlier this year.
Problems persist with DSHEA, according to some who call into question the “Generally Recognized as Safe” designation, as well as issues with new dietary ingredient notifications. Concerns have been raised about the need for more FDA enforcement authority against products that are not actually dietary supplements by definition because they contain non-dietary ingredients such as drugs. These are recapped in Nutritional Outlook’s coverage of CRN’s webinar, "Careful What You Wish For: Pitfalls and Booby Traps of DSHEA 2.0.”
Drug preclusion language in DSHEA is also problematic, as Mister explains in Natural Products Insider. “The industry needs clarity and balance given that the motivation for the provision is an economic one to protect Big Pharma’s investments and incentives to do drug research—supplement innovation and research should matter too,” Mister wrote.
The bottom line: Supplement industry stakeholders should be resolute against allowing FDA to predetermine safe levels of ingredients for dietary supplements, according to Mister. However, “After 27 years, everyone should be thinking about what needs to change (and what must be kept) to preserve the underlying philosophy of DSHEA,” he added in Natural Products Insider coverage.
What do you think? Join the conversation by commenting on the CRN Connect app forum.